Author details

Full Name

Joseph J Eron

Affiliation

ORCID

Career Start Year

1990

Papers

588

H Index

105

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37961119	Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2.	bioRxiv	2024
36594946	Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.	JAMA	2023
36111546	Effects of early human immunodeficiency virus infection on cerebral white matter blood flow autoregulation.	AIDS	2023
36210483	Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.	Clin Infect Dis	2023
36399783	Vaporized Nicotine (E-Cigarette) and Tobacco Smoking Among People With HIV: Use Patterns and Associations With Depression and Panic Symptoms.	Journal of acquired immune deficiency syndromes (1999)	2023
38045374	SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.	bioRxiv	2023
37949070	Dominant CD4<sup>+</sup> TÂ cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV.	Cell Rep Med	2023
37601728	Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers.		2023
37751019	Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.		2023
37745410	Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.	bioRxiv	2023
37650767	African American/Black race, apolipoprotein L1 , and serum creatinine among persons with HIV.	AIDS	2023
37650235	Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.		2023
37650237	Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.	J Infect Dis	2023
37650236	Long COVID After Bamlanivimab Treatment.	J Infect Dis	2023
37650234	Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.	J Infect Dis	2023
37650232	Immune Status and SARS-CoV-2 Viral Dynamics.	J Infect Dis	2023
37650233	Variant-Specific Viral Kinetics in Acute COVID-19.	J Infect Dis	2023
37650231	ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.	J Infect Dis	2023
37650230	Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.	J Infect Dis	2023
37581929	The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.	JCI Insight	2023
37969014	HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo.		2023
37697938	Hospital Readmissions Among Persons With Human Immunodeficiency Virus in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies.	J Infect Dis	2023
37869406	Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.	Open Forum Infect Dis	2023
37283544	Use of Next-Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-COV-2 Pandemic on HIV-1 Diagnosis and Transmission.	J Infect Dis	2023
37279602	One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.	Clin Infect Dis	2023
37149004	Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.	Int J Cardiol	2023
36883578	Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study.	Clin Infect Dis	2023
36763044	Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy.	J Infect Dis	2023
36879789	Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study.		2023
36877848	HIV post-treatment controllers have distinct immunological and virological features.	Proc Natl Acad Sci U S A	2023
37317962	Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy.	J Clin Invest	2023
37068272	Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.	Ann Intern Med	2023
36802755	Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.	Ann Intern Med	2023
36865569	HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells.	Pathog Immun	2023
37437108	Evaluating Clinic-Based Interventions to Reduce Racial Differences in Mortality Among People With Human Immunodeficiency Virus in the United States.	J Infect Dis	2023
37368939	Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV.	J Acquir Immune Defic Syndr	2023
36688441	Corrigendum to: Fusion designs and estimators for treatment effects.		2023
36541638	The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum.	AIDS	2023
36609705	Clinical and Behavioral Outcomes for Transgender Women Engaged in HIV Care: Comparisons to Cisgender Men and Women in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort.		2023
36922393	Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.	Am J Epidemiol	2023
36855253	Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV.	HIV Med	2023
36728918	Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV.	AIDS	2023
36661240	Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.	J Infect Dis	2023
36454551	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.	JAMA	2023
37534689	HIV and urethritis: time required for antiretroviral therapy to suppress HIV in semen.		2023
37099295	Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.	JAMA Netw Open	2023
36723488	Development of Frail RISC-HIV: a Risk Score for Predicting Frailty Risk in the Short-term for Care of People with HIV.	AIDS	2023
36658128	Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.	Nat Commun	2023
35343038	Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort.	HIV Med	2022
36159042	Associations between female birth sex and risk of chronic kidney disease development among people with HIV in the USA: A longitudinal, multicentre, cohort study.	EClinicalMedicine	2022